United-Guardian, Inc. — Q3 2023 Form 10-Q
Reporting period: Three and nine months ended September 30, 2023. The company manufactures and markets cosmetic ingredients, pharmaceuticals, and medical lubricants through Guardian Laboratories. It discontinued its industrial product line after Q2 2023 because of low sales and no growth.
Financial performance
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Net sales | $3.06 million | $2.42 million | $8.28 million | $9.94 million |
| Income from operations | $722,000 | $688,000 | $2.07 million | $3.39 million |
| Net income | $627,000 | $346,000 | $1.84 million | $1.89 million |
| Basic and diluted EPS | $0.14 | $0.07 | $0.40 | $0.41 |
| Operating cash flow | Not stated by quarter | Not stated by quarter | $2.02 million | $1.90 million |
- Q3 sales rose 26% year over year; nine-month sales fell 17%. Q3 sales growth came mainly from cosmetic ingredients (+42%) and medical lubricants (+73%). Nine-month cosmetic ingredient sales declined 37%, while medical lubricant sales fell 18%.
- Gross margin, calculated from reported sales and cost of sales, was about 43% in Q3 versus 55% a year earlier, and 48% for nine months versus 55%. Management cited higher raw-material and freight costs, a greater sales mix of lower-margin pharmaceuticals, and higher per-unit overhead from reduced production.
- Nine-month operating income declined about 39%, while net income declined about 2%. Investment income increased, and marketable-security results improved substantially versus 2022’s losses. Q3 included a $14,000 investment loss; nine-month results included a $66,000 net investment gain.
Financial position and liquidity
- At September 30, cash and cash equivalents were $7.12 million, marketable securities $929,000, and total current assets $11.62 million. Current liabilities were $1.47 million; working capital was $10.14 million and the current ratio was 7.9:1.
- Cash increased by $6.29 million from year-end 2022. Nine-month operating cash flow was $2.02 million; investing activities provided $4.73 million, primarily reflecting sales of marketable securities and reinvestment in short-term Treasury bills. Financing cash outflow was $459,000, all dividends paid.
- No debt is reported on the balance sheet. Management said working capital should support operations for at least the next 12 months. The company expects approximately $100,000 in costs for a building sprinkler-system upgrade.
Management commentary, outlook, and risks
- The company provided no formal sales or earnings guidance. It expects an approximately 21% tax rate for the fiscal year and says liquidity is sufficient for at least 12 months.
- China demand for Lubrajel products remains pressured by a slower-than-expected recovery, lower-priced Asian competitors, and customer inventory adjustments. Supply-chain instability has lengthened some raw-material lead times; inflation or renewed cost increases could further pressure margins.
- On October 10, 2023, the company notified its largest cosmetic-ingredient distributor, Ashland Specialty Ingredients (ASI), that it would not renew the existing exclusive distribution agreement in its current form. The company said it intends to continue the relationship and seek changes addressing declining sales in certain regions. The agreement was due to renew January 1, 2024.
- On October 19, 2023, the company notified the FDA of a potential Renacidin supply shortage. Contract manufacturer Amsino temporarily stopped manufacturing during facility maintenance and follow-up to FDA observations. Delayed orders were expected around February 2 and 9, 2024, and the company said it could run short before delivery. It is taking steps to mitigate the disruption.
- Sales and supplier concentration are notable: four distributors accounted for 80% of nine-month sales and 83% of receivables; two suppliers represented about 74% of nine-month purchases. The company reported no legal proceedings and no changes materially affecting internal control over financial reporting.
Important facts for investors to verify
- Whether Amsino resumed Renacidin production on schedule, and whether any shortage affected shipments, sales, or customers.
- Whether United-Guardian and ASI renegotiated the distribution agreement, and how any revised terms affect sales, exclusivity, and geographic reach.
- Whether cosmetic-ingredient demand, particularly in China, and customer destocking improve; monitor distributor concentration and sales trends.
- Whether pricing actions offset raw-material, freight, labor, and production-cost pressures, and whether gross margins recover.
- Cash generation, investment portfolio positioning, dividend levels, and completion and cost of the sprinkler-system upgrade.